TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$23.31 USD
+0.06 (0.26%)
Updated Sep 24, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 101 - 120 ( 278 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics Presents Final Phase 2 Ublituximab Data in MS at ECTRIMS; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Phase 2 MS Abstract Released With Oral Presentation at ECTRIMS on October 11; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics Announces UNITY-CLL Update in CLL; PT Lowered to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics Reports 2Q18 Results, MS Phase 3 Trials Reach Target Enrollment
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics Completes ULTIMATE I and II Target Enrollment Early
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Updates From TG''s ASCO Analyst and Investor Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
1Q18 Results: Phase 3 UNITY-CLL Data Expected This Summer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Reports Updated 24-Week MS Phase 2 Data at AAN 70th Annual Meeting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Dose Expansion Portion of Phase 1 Initiated for CK-301; First Registration Trial Expected in 1Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
4Q17 Results: Top-Line UNITY-CLL Data in 2Q18; Raising Price Target to $38
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Announces Publication of Umbralisib Data in Lancet Oncology From a Phase 1 First-in-Human Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Presents Six Month Results From Phase 2 Study in MS; Continued Safety and Efficacy Observed With Ublituximab
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Potential BLA Filing in 4Q18 Based on UNITY-CLL Trial; Management Meeting Highlights
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Announces Global License Agreement With Jiangsu Hengrui Medicine for Development of Novel BTK Inhibitors
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Key Takeaways From ASH Investor - Analyst Event; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Announces New Phase 2 Trial in Follicular Lymphoma for Umbralisib
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.